Search for companies, drugs, and catalysts
Phase 2
Development Phase
1
Upcoming Catalysts
0
Historical Events
Regulatory Approvals
SPN-817 Phase 2 Results Expected
SPN-817 • Focal Onset Seizures
Target Indication
Focal Onset Seizures
Clinical Trial
Last updated: 12/4/2025
SUPN
SUPERNUS PHARMACEUTICALS, INC.